Question follow-through · 17966

Autoimmune Diseases: Health Education and Research

To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) support research into and (b) promote awareness of (i) Guillain-Barré Syndrome, (ii) Chronic Inflammatory Demyelinating Polyneuropathy and (iii) other related inflamm

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body
Department of Health and Social Care
Tabled
4 Dec 2024
Target answer date
6 Dec 2024
Answer
11 Dec 2024 · 7 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Recorded timeline

  1. 4 Dec 2024

    Question tabled

    To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) support research into and (b) promote awareness of (i) Guillain-Barré Syndrome, (ii) Chronic Inflammatory Demyelinating Polyneuropathy and (iii) other related inflamm

  2. 6 Dec 2024

    Target answer date

    Date supplied by the official written-questions record.

  3. 11 Dec 2024

    Answer published

    The Government is committed to improving the lives of those living with rare diseases, such as rare inflammatory neuropathies. The UK Rare Diseases Framework sets out four priorities, collaboratively developed with the rare disease community, which includ...

Open official record

Official data retrieved 27 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Propranolol

21 May 2026 · To ask the Secretary of State for Health and Social Care, what progress has been made on securing an adequate supply of propranolol 80mg and 160mg modified release capsules.